ATC Group: B02BX09 Fostamatinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B02BX09 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B02 Antihemorrhagics
3 B02B Vitamin K and other hemostatics
4 B02BX Other systemic hemostatics
5 B02BX09

Active ingredients in B02BX09

Active Ingredient Description
Fostamatinib

Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK), through its major metabolite R406. R406 reduces antibody-mediated destruction of platelets. Fostamatinib is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients.

Related product monographs

Title Information Source Document Type  
TAVALISSE Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TAVLESSE Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Estonia (EE)

Finland (FI)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Poland (PL)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.